Exploring therapeutic strategies for candidiasis: From current treatments to future perspectives

The rising prevalence of antifungal resistance in Candida species poses a significant challenge to public health, necessitating the exploration of novel therapeutic strategies. This review highlights advancements in molecular innovations targeting Candida infections, emphasizing novel drug discovery approaches, including high-throughput screening, structure-based drug design, and synthetic modifications of existing molecules. We discuss emerging drug candidates in preclinical and clinical development, targeting key fungal pathways such as ergosterol biosynthesis, β-(1,3)-D-glucan synthesis, and novel metabolic regulators. Furthermore, drug repurposing strategies, leveraging known pharmacokinetics and pharmacodynamics of existing drugs, provide accelerated routes to new antifungal treatments. Collaborative efforts integrating pharmaceutical research, clinical insights, and technological advancements are imperative for the development of next-generation antifungal therapeutics. This review underscores the need for an interdisciplinary approach to antifungal drug discovery, ensuring effective and sustainable treatment options against resistant Candida strains.